AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23559332 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 IU/day
Number of subjects: 169
Study 21157026 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine (16 to 24 mg/day)
Number of subjects: 18
Study 19692371 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal pegaptanib (IVP) 0.3 mg every 6 weeks for 30 weeks
Number of subjects: 20
Study 19692371 — intervention group
Group type: COMPARATOR
Intervention: Panretinal laser photocoagulation (PRP)
Number of subjects: 20
Study 19692371 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal pegaptanib (IVP)
Number of subjects: 20
Study 17597085 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month dietary regimen
Number of subjects: 46
Study 14724039 — intervention group
Group type: EXPERIMENTAL
Intervention: 50‐mg oral naltrexone
Number of subjects: 44
Study 11431296 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (12.5 mg zinc sulphate daily for six days a week for six months)
Number of subjects: 709
Study 11431296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 709
Study 11431296 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 709
Study 9741901 — intervention group
Group type: EXPERIMENTAL
Intervention: New sustained-release formulation of amoxicillin (500 mg)
Number of subjects: 12
Study 9741901 — intervention group
Group type: COMPARATOR
Intervention: Conventional gelatin capsule of amoxicillin (500 mg)
Number of subjects: 12
Study 8285810 — intervention group
Group type: EXPERIMENTAL
Intervention: Manufacturer-associated NSAIDs
Number of subjects: 180
Study 8285810 — intervention group
Group type: COMPARATOR
Intervention: Comparison drug
Number of subjects: 180
Study 3172062 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (from puerperal day 1 to 14)
Number of subjects: 43
Study 3172062 — intervention group
Group type: COMPARATOR
Intervention: Prostaglandin E2 (from day 3 or 4 for 24 hours)
Number of subjects: 43
Study 29604311 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulations containing silicone particles
Number of subjects: 0
Study 29604311 — intervention group
Group type: COMPARATOR
Intervention: Formulations containing Microsponge® particles (control)
Number of subjects: 0
Study 26992875 — intervention group
Group type: EXPERIMENTAL
Intervention: Older individuals with SMI and diabetes
Number of subjects: 200
Study 26992875 — intervention group
Group type: COMPARATOR
Intervention: Younger individuals with SMI and diabetes
Number of subjects: 200
Study 26992875 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with major depressive disorder
Number of subjects: 200
Study 24561971 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track (FT) nutrition management
Number of subjects: 464
Study 24561971 — intervention group
Group type: COMPARATOR
Intervention: Traditional nutrition management
Number of subjects: 464
Study 22190010 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth assessment
Number of subjects: 20
Study 22190010 — intervention group
Group type: COMPARATOR
Intervention: In-person assessment
Number of subjects: 20
Study 20863241 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface preparation with 37% phosphoric acid for 30 s
Number of subjects: 59
Study 20863241 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface preparation with 0.5‐W Er,Cr:YSGG laser for 6 s
Number of subjects: 59
Study 20863241 — intervention group
Group type: EXPERIMENTAL
Intervention: No surface preparation
Number of subjects: 59
Study 20863241 — intervention group
Group type: COMPARATOR
Intervention: Conventional bleaching procedure (without surface preparation)
Number of subjects: 59
Study 18851795 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine (500 mg/m2)
Number of subjects: 92
Study 18851795 — intervention group
Group type: COMPARATOR
Intervention: Glutamine (1500 mg/m2)
Number of subjects: 92
Study 17119688 — intervention group
Group type: EXPERIMENTAL
Intervention: Patey technique (resection of pectoralis minor muscle)
Number of subjects: 426
Study 17119688 — intervention group
Group type: EXPERIMENTAL
Intervention: Madden technique (preservation of pectoralis minor muscle)
Number of subjects: 426
Study 17119688 — intervention group
Group type: COMPARATOR
Intervention: Both techniques
Number of subjects: 426
Study 12534506 — intervention group
Group type: EXPERIMENTAL
Intervention: Moist Exposed Burn Ointment (MEBO)
Number of subjects: 0
Study 12534506 — intervention group
Group type: COMPARATOR
Intervention: Tegaderm (semipermeable membrane occlusive dressing)
Number of subjects: 0
Study 11408134 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthesia
Number of subjects: 100
Study 11408134 — intervention group
Group type: COMPARATOR
Intervention: Sub‐Tenon's anesthesia
Number of subjects: 100
Study 9414364 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergonomics training
Number of subjects: 104
Study 9414364 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 104
Study 8430216 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 10mg (ZP)
Number of subjects: 6
Study 8430216 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 1mg (FN)
Number of subjects: 6
Study 8430216 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.25mg (TZ)
Number of subjects: 6
Study 8430216 — intervention group
Group type: EXPERIMENTAL
Intervention: Levomepromazine 5mg (LP)
Number of subjects: 6
Study 8430216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 3306904 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide (4 mg nocte)
Number of subjects: 60
Study 29544534 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 414
Study 29544534 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 414
Study 29544534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 414
Study 29544534 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoinjector usability
Number of subjects: 414
Study 29354971 — intervention group
Group type: EXPERIMENTAL
Intervention: Flipping moxibustion of Hui medicine combined with western medication
Number of subjects: 80
Study 29354971 — intervention group
Group type: COMPARATOR
Intervention: Simple western medication (oral methotrexate and sulfasalazine)
Number of subjects: 80
Study 25701866 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine-artesunate (MQAS)
Number of subjects: 270
Study 25701866 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine plus amodiaquine (SPAQ)
Number of subjects: 270
Study 25701866 — intervention group
Group type: COMPARATOR
Intervention: Daily proguanil
Number of subjects: 270
Study 24149984 — intervention group
Group type: EXPERIMENTAL
Intervention: Totally endoscopic surgery
Number of subjects: 708
Study 24149984 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 708
Study 22476119 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin 1 gm tid for 7 days
Number of subjects: 98
Study 22476119 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 200 mg bid for 7 days
Number of subjects: 98
Study 22476119 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin 1 gm tid for 7 days (excluding Child-Pugh A and patients without ascites)
Number of subjects: 98
Study 22476119 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 200 mg bid for 7 days (excluding Child-Pugh A and patients without ascites)
Number of subjects: 98
Study 18236372 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab (20 mg immediately following surgery and four days postoperatively)
Number of subjects: 20
Study 18236372 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin A (CSA, adapted to blood-trough level 120-150 ng/mL for six months)
Number of subjects: 20
Study 16724499 — intervention group
Group type: EXPERIMENTAL
Intervention: Allevyn hydro-cellular dressings
Number of subjects: 441
Study 12679436 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin (1.0 micro g/kg iv)
Number of subjects: 34
Study 11028147 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac pacemakers
Number of subjects: 0
Study 11028147 — intervention group
Group type: COMPARATOR
Intervention: Different pacing modes
Number of subjects: 0
Study 9364537 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (100 mg/m2, intravenous infusion for 1 hour once every 3 weeks)
Number of subjects: 200
Study 9364537 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin (75 mg/m2, intravenous infusion for 15 to 20 minutes once every 3 weeks)
Number of subjects: 200
Study 31561652 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.5% (20 mL) only (group B)
Number of subjects: 90
Study 31561652 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% + 10 mg morphine (group BM10)
Number of subjects: 90
Study 31561652 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% + 15 mg morphine (group BM15)
Number of subjects: 90
Study 29206761 — intervention group
Group type: COMPARATOR
Intervention: Placebo arm of an ongoing prospective clinical trial
Number of subjects: 55
Study 27364096 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphtheria, tetanus, and polio booster vaccines
Number of subjects: 0
Study 27364096 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertussis toxoid
Number of subjects: 0
Study 24686884 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolongation Of Life (POL) format
Number of subjects: 240
Study 24686884 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute Risk Reduction (ARR) format
Number of subjects: 240
Study 22472339 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (0.4 mg daily)
Number of subjects: 24
Study 22472339 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intake of folic acid (not specified)
Number of subjects: 24
Study 18727841 — intervention group
Group type: COMPARATOR
Intervention: r‐hFSH and r‐hLH 0 IU/day
Number of subjects: 34
Study 18727841 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐hFSH and r‐hLH 25 IU/day
Number of subjects: 34
Study 18727841 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐hFSH and r‐hLH 75 IU/day
Number of subjects: 34
Study 18727841 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐hFSH and r‐hLH 225 IU/day
Number of subjects: 34
Study 18727841 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐hFSH alone
Number of subjects: 34
Study 18727841 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐hFSH and r‐hLH (all doses)
Number of subjects: 34
Study 18727841 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐hLH
Number of subjects: 34
Study 16480403 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 215
Study 16480403 — intervention group
Group type: COMPARATOR
Intervention: Antireflux surgery
Number of subjects: 215
Study 12623561 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct stenting
Number of subjects: 401
Study 12623561 — intervention group
Group type: COMPARATOR
Intervention: Stenting after predilatation
Number of subjects: 401
Study 10665496 — intervention group
Group type: COMPARATOR
Intervention: CP-122,288 (31.25 microg intravenously)
Number of subjects: 0
Study 10665496 — intervention group
Group type: COMPARATOR
Intervention: CP-122,288 (doses between 3.125 and 312.5 microg orally)
Number of subjects: 0
Study 9313057 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin administered intravenously (200 to 400 mg) or orally (500 to 750 mg) twice a day for 6 to 21 days
Number of subjects: 22
Study 9313057 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 22
Study 8317647 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of ginger
Number of subjects: 16
Study 8317647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 3549586 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 0
Study 3549586 — intervention group
Group type: COMPARATOR
Intervention: Bandaging
Number of subjects: 0
Study 3549586 — intervention group
Group type: COMPARATOR
Intervention: Plaster cast immobilisation
Number of subjects: 0
Study 3549586 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 0
Study 31969155 — intervention group
Group type: EXPERIMENTAL
Intervention: Primaquine (radical cure)
Number of subjects: 1
Study 31969155 — intervention group
Group type: EXPERIMENTAL
Intervention: G6PD point-of-care test
Number of subjects: 1
Study 31969155 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal treatment with primaquine
Number of subjects: 1
Study 29234136 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 46
Study 29234136 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 46
Study 29234136 — intervention group
Group type: COMPARATOR
Intervention: Active vs. Sham tDCS
Number of subjects: 46
Study 26472297 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive therapeutic exercise program consisting of 6 progressive therapeutic exercise modules including proprioceptive low-load progressive craniocervical and cervical exercises and high-load exercises for the neck muscles.
Number of subjects: 0
Study 26472297 — intervention group
Group type: COMPARATOR
Intervention: Sham TENS treatment sessions (control group)
Number of subjects: 0
Study 24825642 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab (140 mg every 2 weeks)
Number of subjects: 2067
Study 24825642 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab (420 mg monthly)
Number of subjects: 2067
Study 24825642 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg daily)
Number of subjects: 2067
Study 24825642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2067
Study 24825642 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 2067
Study 23186260 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 5% i.u. infusion (140 ml)
Number of subjects: 12
Study 23186260 — intervention group
Group type: COMPARATOR
Intervention: Saline i.u. infusion (140 ml)
Number of subjects: 12
Study 20693158 — intervention group
Group type: EXPERIMENTAL
Intervention: gemfibrozil, niacin, and cholestyramine in combination
Number of subjects: 143
Study 20693158 — intervention group
Group type: COMPARATOR
Intervention: matching placebos
Number of subjects: 143
Study 18325911 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (IV) - received staff asthma training, advice on asthma policy, emergency beta(2)-agonist inhaler with spacer, and asthma lesson
Number of subjects: 193
Study 18325911 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (IV)
Number of subjects: 193
Study 18325911 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (IV) - girls
Number of subjects: 193
Study 18325911 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention group (NI) - girls
Number of subjects: 193
Study 18325911 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention group (NI) and Intervention group (IV) - non-asthmatic peers
Number of subjects: 193
Study 16002168 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG asymmetry in the alpha range
Number of subjects: 99
Study 12930247 — intervention group
Group type: EXPERIMENTAL
Intervention: LocaLisa three-dimensional nonfluoroscopic imaging system
Number of subjects: 52
Study 12930247 — intervention group
Group type: COMPARATOR
Intervention: Standard fluoroscopy
Number of subjects: 52
Study 10713636 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate processing of PBPC
Number of subjects: 68
Study 10713636 — intervention group
Group type: COMPARATOR
Intervention: Overnight storage of PBPC
Number of subjects: 68
Study 9377615 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone buteprate 0.1% cream
Number of subjects: 194
Study 9377615 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cream base)
Number of subjects: 194
Study 1545040 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 355
Study 1545040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 355
Study 4085354 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg/d
Number of subjects: 8
Study 4085354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 29661838 — intervention group
Group type: EXPERIMENTAL
Intervention: MitoQ (20 mg/d)
Number of subjects: 20
Study 29661838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 27770252 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based camera navigation training (camera group)
Number of subjects: 36
Study 27770252 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based cholecystectomy training (procedure group)
Number of subjects: 36
Study 27770252 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 36
Study 25697463 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance analysis (BIA)
Number of subjects: 89
Study 25697463 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-energy x-ray absorptiometry (DXA)
Number of subjects: 89
Study 24442048 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutraceutical (Q10 coenzyme, Krill-oil, lipoic acid, resveratrol, Vitis vinifera seed oil, vitamin E, selenium) in addition to etanercept therapy
Number of subjects: 40
Study 24442048 — intervention group
Group type: COMPARATOR
Intervention: Etanercept therapy alone
Number of subjects: 40
Study 20829340 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete mediastinal lymphadenectomy
Number of subjects: 524
Study 18502911 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgery (microdiscectomy)
Number of subjects: 283
Study 18502911 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (intended six months of continued conservative treatment)
Number of subjects: 283
Study 18502911 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 283
Study 16574893 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg torcetrapib once daily for 4 weeks
Number of subjects: 19
Study 16574893 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg torcetrapib twice daily for an additional 4 weeks (nonatorvastatin group)
Number of subjects: 19
Study 16574893 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg torcetrapib on a background of atorvastatin
Number of subjects: 19
Study 16574893 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (20 mg)
Number of subjects: 19
Study 14627307 — intervention group
Group type: EXPERIMENTAL
Intervention: S(+)-ketamine/midazolam
Number of subjects: 100
Study 14627307 — intervention group
Group type: COMPARATOR
Intervention: Racemic ketamine/midazolam
Number of subjects: 100
Study 11789169 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 ml gastrointestinal dialysate (non‐absorbed mannitol solution) orally 2‐3 times a day
Number of subjects: 57
Study 11789169 — intervention group
Group type: EXPERIMENTAL
Intervention: XQN 5‐10 tablets 3 times per day combined with 1000 ml gastrointestinal dialysate (non‐absorbed mannitol solution) orally 2‐3 times a day
Number of subjects: 57
Study 11789169 — intervention group
Group type: COMPARATOR
Intervention: Coated aldehyde oxystarch 5‐10 g, 3 times a day
Number of subjects: 57
Study 9169964 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide and thiamine (A + T)
Number of subjects: 33
Study 8455235 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical bacillus Calmette-Guerin (BCG) administration
Number of subjects: 94
Study 3523636 — intervention group
Group type: EXPERIMENTAL
Intervention: Ornidazole (2.5 g/m2, administered orally, two times weekly for 3 weeks, total dose 15 g/m2)
Number of subjects: 23
Study 3523636 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered orally, two times weekly for 3 weeks)
Number of subjects: 23
Study 3523636 — intervention group
Group type: EXPERIMENTAL
Intervention: Ornidazole (serum concentration)
Number of subjects: 23
Study 3523636 — intervention group
Group type: EXPERIMENTAL
Intervention: Ornidazole (tumour tissue concentration)
Number of subjects: 23
Study 30739217 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing-retraining plus exercise-training using acoustic feedback
Number of subjects: 205
Study 30739217 — intervention group
Group type: COMPARATOR
Intervention: Exercise-training alone
Number of subjects: 205
Study 30739217 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing-retraining plus exercise-training
Number of subjects: 205
Study 28913570 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 269
Study 26986188 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 40
Study 26986188 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TENS)
Number of subjects: 40
Study 23410186 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine (50 to 100 μg)
Number of subjects: 0
Study 23410186 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine (5 to 10 mg)
Number of subjects: 0
Study 21085038 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity exercise (30% HR reserve)
Number of subjects: 40
Study 21085038 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (70% HR reserve)
Number of subjects: 40
Study 21085038 — intervention group
Group type: COMPARATOR
Intervention: Control group (sedentary postpartum women)
Number of subjects: 40
Study 19910821 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-method, part-body cooling intervention (20-minute duration)
Number of subjects: 7
Study 19910821 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-method, part-body cooling intervention
Number of subjects: 7
Study 19910821 — intervention group
Group type: COMPARATOR
Intervention: No cooling intervention (Control)
Number of subjects: 7
Study 17118491 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum (sugar-free or regular) for 15 min hourly after lunch
Number of subjects: 60
Study 17118491 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum (sugar-free or regular)
Number of subjects: 60
Study 17118491 — intervention group
Group type: COMPARATOR
Intervention: No-gum
Number of subjects: 60
Study 15789977 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate 360 degrees
Number of subjects: 20
Study 15789977 — intervention group
Group type: COMPARATOR
Intervention: Oral‐B Indicator
Number of subjects: 20